ALLMedicine™ Prostate Cancer Center

Jun 26th, 2022 - Radical prostatectomy and radical radiotherapy have equivalent survival outcomes in the treatment of localised prostate cancer but differing side-effect profiles. The 2018 Faculty of Radiation Oncology of the Royal Australasian College of Radiolog...

Jun 26th, 2022 - Apalutamide (APA) is a next-generation androgen receptor antagonist for the treatment of advanced prostate cancer. We have previously shown that upregulation of autophagy is one of the mechanisms by which prostate cancer (PC) cells survive APA ant...

Jun 26th, 2022 - Prostate cancer (PCa) screening is not routinely conducted in men aged 55 and younger, although this age group accounts for more than 10% of cases. Polygenic risk scores (PRSs) and patient data applied toward early prediction of PCa may lead to ea...

Jun 25th, 2022 - Large-scale prostate cancer (PCa) database reviews have found a consistent discrepancy in the mortality rate in Black patients compared to their White counterparts. Furthermore, differences in PCa treatment and outcomes among Black men of differen...

Jun 25th, 2022 - To investigate the prognostic value and potential therapeutic target of the baseline serum hormones in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone. This retrospective study was performed in patien...

May 20th, 2022 - The American College of Radiology (ACR), American Brachytherapy Society (ABS), and American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for transperineal permanent brachytherapy of prostate cancer...

May 11th, 2022 - The summary presented herein represents Part III of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of radiation and offering several future directions of further relevant study i...

May 11th, 2022 - The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of active surveillance and surgery as well as follow-up for patients after prima...

May 11th, 2022 - The summary presented herein represents Part I of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment, staging, and risk-based management in patients diagnosed with clinically lo...

May 10th, 2022 - The recommendations discussed herein for the management of clinically localized prostate cancer provide a framework stratified by risk to facilitate care decisions and guide clinicians in the implementation of selected management options.

Jun 24th, 2022 - Background: Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. Urothelial Carcinoma (UC)...

Jun 24th, 2022 - Background: Pilot study to evaluate the feasibility of real time ultrasound imaging to guide focal thermal ablation of low risk focal prostate tumors Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 t...

Jun 24th, 2022 - Background: Prostate cancer is one of the most common malignancies occurring in men. While many men will qualify for active surveillance (AS), those with intermediate risk disease are often recommended definitive therapy despite the morbidity. Foc...

Jun 24th, 2022 - Background: Zolpidem is currently approved for the treatment of patients with insomnia. Women reported experiencing an increased incidence of adverse effects than men, resulting in a reduction of the recommended dose of zolpidem for women. Zolpide...

Jun 24th, 2022 - Background: Enzalutamide is a well-tolerated, modern androgen receptor antagonist (ARA) with more enhanced anti-tumor activity compared to previous ARAs. Phase III trial has demonstrated a 4.8 month improvement in survival and a 37% risk reduction...

Jun 23rd, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

Jun 23rd, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

Jun 17th, 2022 - NEW YORK (Reuters Health) - MRI-guided focused ultrasound (MRgFUS) continues to show promise in men with intermediate-risk prostate cancer, with effective disease control and fewer side effects relative to other treatments, according to new resear...

Jun 17th, 2022 - This study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Compared with observation, active treatment lowers the risk for overall and prostate cancer-specific death in men with localized prostate...

Jun 10th, 2022 - The way we treat prostate cancer has changed dramatically in recent years. Advances in MRI imaging have undoubtedly contributed to this change, both in terms of diagnosis — by making targeted biopsies possible — and in terms of our approach to tre...